178 completed, 23 unknown, 13 terminated, 12 recruiting. 241 Phase 3, 18 Phase 2.
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®) - Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH) | Phase 3 | Recruiting | YS Life Science Co., Ltd. | 600 | 2026-06-02 | 2026-09-23 |
| Efficacy and Safety of DNN.31.19.026 for Ocular Hypertension or Primary Open-Angle Glaucoma Product DNN.31.19.026, COSOPT® - Ocular Hypertension, Primary Open Angle Glaucoma | Phase 3 | Not yet recruiting | Ache Laboratorios Farmaceuticos S.A. | 336 | 2026-06-01 | 2026-06-01 |
| Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension QLS-111-FDC, Latanoprost (0.005%) - OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension | Phase 2 / Phase 3 | Completed | Qlaris Bio, Inc. | 64 | 2026-03-18 | 2026-07-29 |
| Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure - Glaucoma | Phase 3 | Recruiting | Glaukos Corporation | 510 | 2026-02-17 | 2026-03-30 |
| Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension HUC3-637, HUC3-637-R - Primary Open Angle Glaucoma (POAG), Ocular Hypertension | Phase 3 | Recruiting | Huons Co., Ltd. | 206 | 2026-01-01 | 2026-01-13 |
| [KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension TFC-003, TFC-003-R1, TFC-003-R2+TFC-003-R3 - Glaucoma Open-Angle Primary, Ocular Hypertension | Phase 3 | Recruiting | Kukje Pharma | 188 | 2025-12-09 | 2026-06-23 |
| Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone) Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5% - Cataract, Glaucoma | Phase 3 | Recruiting | SpyGlass Pharma, Inc. | 400 | 2025-10-28 | 2025-10-20 |
| Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5% - Cataract, Glaucoma | Phase 3 | Recruiting | SpyGlass Pharma, Inc. | 400 | 2025-10-15 | 2025-10-20 |
| Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution - Ocular Hypertension, Open Angle Glaucoma | Phase 3 | Completed | Alcon Research | 489 | 2025-09-02 | 2026-04-21 |
| The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Placebo - Pseudophakic Bullous Keratopathy, Glaucoma | Phase 2 / Phase 3 | Completed | University Hospital Dubrava | 50 | 2025-05-12 | 2026-09-09 |
| A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma XEN63 Glaucoma Treatment System - Primary Open Angle Glaucoma | Phase 3 | Recruiting | AbbVie | 130 | 2025-02-11 | 2026-10-09 |
| Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation Surgery Mitomycin c - Glaucoma | Phase 3 | Not yet recruiting | St. Joseph's Healthcare Hamilton | 144 | 2024-12-01 | 2024-11-08 |
| A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China DE-117B Eye Drops, Latanoprost - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Active not recruiting | Santen Pharmaceutical Co., Ltd. | 345 | 2024-11-28 | 2026-05-15 |
| Nicotinamide Supplementation in Glaucoma Nicotinamide Tablet, Nicotinamide Placebo - Glaucoma | Phase 3 | Enrolling by invitation | Singapore Eye Research Institute | 520 | 2024-03-12 | 2024-12-12 |
| Effect of Fixed Combination Citicoline Homotaurine and Pyrroloquinoline Quinone on Pattern-electroretinogram in Glaucoma Citicoline 500 mg plus Homotaurine 50 mg plus Pyrroloquinoline quinone (Neuprozin Mito® ) - Glaucoma, Neuroprotection | Phase 3 | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 40 | 2024-01-27 | 2025-05-01 |
| Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial Nicotinomide, Matching placebo - Glaucoma, Open-Angle | Phase 3 | Recruiting | University College, London | 496 | 2024-01-18 | 2024-05-09 |
| Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution NCX 470, Placebo - Open Angle Glaucoma | Phase 2 / Phase 3 | Completed | Nicox Ophthalmics, Inc. | 18 | 2023-12-12 | 2025-09-08 |
| Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma Citicoline eye drops 2%, Placebo - Glaucoma, Open-Angle | Phase 3 | Recruiting | Omikron Italia S.r.l. | 1000 | 2023-12-11 | 2024-03-12 |
| Travoprost Intraocular Implant in Conjunction With Cataract Surgery iDose TR - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Unknown | Glaukos Corporation | 60 | 2023-09-11 | 2024-06-03 |
| Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study Dietary supplements - Nicotinamide and Pyruvate, Placebo - Primary Open Angle Glaucoma | Phase 2 / Phase 3 | Active not recruiting | Columbia University | 250 | 2023-03-14 | 2026-07-15 |
Showing 20 of 241. Sign in to see all of them.
Ocular Hypertension (155) · Glaucoma, Open-Angle (146) · Hypertension (9) · Cataract (8) · Glaucoma, Neovascular (8) · Glaucoma, Angle-Closure (5) · Pterygium (4) · Exfoliation Syndrome (3) · Choroidal Neovascularization (1) · Corneal Edema (1) · Diabetic Retinopathy (1) · Eye Diseases (1) · Fibrosis (1) · Hydrophthalmos (1)
Eye Diseases (240) · Ocular Hypertension (86) · Cardiovascular Diseases (11) · Vascular Diseases (11) · Lens Diseases (8) · Conjunctival Diseases (4) · Uveal Diseases (4) · Iris Diseases (3) · Retinal Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Retinal Degeneration (2) · Amino Acid Metabolism, Inborn Errors (1)
Latanoprost (40) · Timolol (40) · Travoprost (28) · Ophthalmic Solutions (24) · brinzolamide (19) · Bimatoprost (15) · Brimonidine Tartrate (13) · Xalacom (9) · dorzolamide (9) · netarsudil (9) · dorzolamide-timolol combination (8) · Duotrav (7) · tafluprost (6) · BID protein, human (5) · Brimonidine Tartrate, Timolol Maleate Drug Combination (5)
Alcon Research (45) · Allergan (18) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (11) · Santen Pharmaceutical Co., Ltd. (11) · Pro Top & Mediking Company Limited (9) · Aerie Pharmaceuticals (8) · Glaukos Corporation (7) · AbbVie (6) · Merck Sharp & Dohme LLC (5) · National Eye Institute (NEI) (5) · Santen Oy (5) · Bausch & Lomb Incorporated (4) · Laboratoires Thea (4) · Laboratorios Sophia S.A de C.V. (3) · Nicox Ophthalmics, Inc. (3)
United States (87) · Japan (15) · United Kingdom (15) · Canada (13) · France (12) · Germany (12) · Italy (12) · China (11) · Singapore (10) · South Korea (10) · Australia (9) · Belgium (9) · Russia (9) · Brazil (8) · Poland (8)
Theresa Heah, MD (4) · Auli Ropo, M.D. (2) · James Teague, BS, Sr. Clinical Manager (2) · Jason Vittitow (2) · Jeff Wells, PharmD, MBA (2) · Luca Rossetti, MD (2) · Margot Goodkin (2) · Marlene R Moster, MD (2) · Pamela Smith, B.S. (2) · Paul Yoo, OD (2)
PMID 35943114, PMID 10937547, PMID 19427617, PMID 36912740, PMID 17122118, PMID 29194198, PMID 32166538, PMID 35643967, PMID 36378864, PMID 37010901, PMID 38985408, PMID 39240530, PMID 17459480, PMID 18289898, PMID 18414108, PMID 18534052, PMID 18538406, PMID 19152871, PMID 19365194, PMID 19683191, PMID 19850848, PMID 20142538, PMID 20212196, PMID 20346127, PMID 20828829, PMID 20874498, PMID 21467178, PMID 21735753, PMID 21843876, PMID 21851642, PMID 22310086, PMID 22814041, PMID 23579344, PMID 24667994, PMID 24727262, PMID 24794283, PMID 24906863, PMID 25019269, PMID 25429421, PMID 25430900, PMID 25447269, PMID 25613811, PMID 25826644, PMID 25893514, PMID 26875002, PMID 27210275, PMID 27292765, PMID 27450828, PMID 27457469, PMID 27526051
2014 (3), 2008 (2), 2015 (2), 2018 (2), 2009 (1), 2023 (1), 2UG1EY031651-06 (1), R01EY014957 (1), U10EY009307 (1), U10EY009341 (1), UG1EY031651 (1)